Axogen (NASDAQ: AXGN) — Perfil da empresa, notícias e dados financeiros
Axogen specializes in surgical solutions for peripheral nerve injuries, aiming to improve patient quality of life.
Axogen
Axogen (NASDAQ:AXGN) specializes in innovative solutions for peripheral nerve injuries. The company is deeply involved in the development and commercialization of surgical nerve repair solutions that aim to restore functionality and improve the quality of life for patients suffering from physical damage or trauma to peripheral nerves. This ambitious objective is pursued through a diverse portfolio of products including Avance® Nerve Graft, AxoGuard® Nerve Connector, and AxoGuard® Nerve Protector, among others, each designed to address different aspects of nerve repair and protection. Axogen's projects range from research and development in nerve regeneration to clinical studies aimed at advancing the field of peripheral nerve repair. The company's overarching goal is to continue pioneering in the nerve repair space, striving to bring innovative and effective treatments to patients worldwide.
Resumo
Operações
Produtos e/ou serviços de Axogen
- Avance Nerve Graft, a biologically based extracellular matrix for peripheral nerve reconstruction.
- Axoguard Nerve Connector, a coaptation aid for tensionless repair of severed nerves.
- Axoguard Nerve Protector, designed to protect and isolate the nerve and reduce the formation of neuromas.
- Axoguard Nerve Cap, specifically developed to prevent neuroma formation at the nerve endings.
- Acroval Neurosensory & Motor Testing System, provides comprehensive diagnostic information for evaluating peripheral nerve injuries.
- Axogen's Education and Training services, aimed at surgeons and medical personnel to advance the understanding and application of nerve repair solutions.
equipe executiva do Axogen
- Michael D. DalePresident, CEO & Director
- Lindsey HartleyChief Financial Officer
- Erick DeVinneyChief Scientific Officer
- Marc A. BeganExecutive VP, General Counsel, Secretary & Chief Compliance Officer
- Jens Schroeder KempChief Marketing Officer
- Craig A. SwandalSenior Vice President of Operations
- Harold D. TamayoVice President of Finance & Investor Relations
- Ivica DucicChief Medical Officer
- Doris QuackenbushChief Revenue Officer
- Rick DittoVice President of Global Health Economics, Reimbursement & Policy
Últimas notícias sobre a Axogen
Histórico de dividendos
Dividendos por ação pagos pela Axogen, por ano fiscal.
| Ano fiscal | Intermediário | Final | Especial | Total |
|---|---|---|---|---|
| FY2010 | — | — | — | $1.0000 |
| FY2005 | — | — | — | $0.0600 |
| FY1992 | — | — | — | $0.0417 |
Principais indicadores financeiros
Resultados divulgados pela Axogen, em USD.
- Cap. de mercado
- 2,9 bi
- Receita (TTM)
- 251,2 mi
- P/L
- —
- LPA (diluído, TTM)
- -0.6
- Dividend yield
- —
- Margem de lucro
- -13.4%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 225,2 mi | -7,8 mi | -15,7 mi | |
| 187,3 mi | -3,3 mi | -10 mi | |
| 159 mi | -21,5 mi | -21,7 mi | |
| 138,6 mi | -29,7 mi | -28,9 mi |